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Background. Influenza remains a major threat to public health. Live-attenuated influenza vaccines (LAIV) have been shown 
to be effective, particularly in children. Follicular T helper (TFH) cells provide B-cell help and are crucial for generating long-term 
humoral immunity. However the role of TFH cells in LAIV-induced immune responses is unknown.
Methods.  We collected tonsils, plasma, and saliva samples from children and adults receiving LAIV prior to tonsillectomy. We 
measured influenza-specific TFH-cell responses after LAIV by flow cytometry and immunohistochemistry. Systemic and local anti-
body responses were analysed by hemagglutination inhibition assay and enzyme-linked immunosorbent assay.
Results.  We report that LAIV induced early (3–7 days post-vaccination) activation of tonsillar follicles and influenza-specific 
TFH-cell (CXCR5+CD57+CD4+ T cell) responses in children, and to a lesser extent in adults. Serological analyses showed that LAIV 
elicited rapid (day 14) and long-term (up to 1 year post-vaccination) antibody responses (hemagglutination inhibition, influenza-
specific IgG) in children, but not adults. There was an inverse correlation between pre-existing influenza-specific salivary IgA con-
centrations and tonsillar TFH-cell responses, and a positive correlation between tonsillar TFH-cell and systemic IgG induction after 
LAIV.
Conclusions.  Our data, taken together, demonstrate an important role of tonsillar TFH cells in LAIV-induced immunity in 
humans.
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Influenza virus infects all ages and can cause major respira-
tory illness such as fulminant pneumonia. Influenza viruses 
are estimated to infect 5%–10% of adults and 20%–30% of 
children annually, resulting in up to 650  000 deaths globally 
[1]. Vaccination is the most cost-effective public health strategy 
to combat annual seasonal influenza [2]. Inactivated influenza 
vaccine (IIV) is used worldwide, and live-attenuated influenza 
vaccine (LAIV) is currently licensed for use in United States, 
Canada, and Europe (Ann Arbor backbone-LAIV), as well as in 
Russia and India (Leningrad backbone-LAIV). Currently used 
seasonal IIV induces strain-specific antibodies up to 6 months 
postvaccination, but it generally does not elicit broadly 
protective antibodies or long-lived memory B-cells [2, 3]. In 
contrast, LAIV elicits persistent antibodies, memory B-cell and 
CD4+ T-cell responses, as well as cross-reactive CD8+ T cells for 
up to 1 year in young children [4–8]; however, LAIV is less ef-
ficacious in adults [9]. The immunological mechanisms for the 
better effectiveness of LAIV in children than in adults are not 
fully understood.
The germinal center (GC) response is vital in the genera-
tion of high-affinity antibodies, long-lived plasma cells, and 
memory B cells after vaccination. Follicular T helper (TFH) cells 
are a subgroup of CD4+ T cells that help antigen-activated B 
cells through proliferation and affinity maturation inside fol-
licles and GCs [10–17]. Follicular T helper cells express che-
mokine receptor CXCR5, inducible T-cell costimulator (ICOS), 
programmed cell death-1 (PD1), and transcriptional factor 
Bcl6 as canonical features. A subset of TFH cells localized in fol-
licles and GCs expresses CD57 [18, 19]. Recent studies revealed 
a transient T-cell type, designated as circulating TFH-like cells 
(CD4+CXCR5+CXCR3+ T cells [20–22] or CD4+CXCR5+PD1+I
COS+CD38+ T cells [23]), in the peripheral blood at 7 days after 
seasonal IIV. These cells provided help to memory B cells and 
correlated with the plasmablast and antibody responses after 
IIV [20–23]. However, it is not known whether LAIV elicits 







niversitetsbiblioteket i Bergen user on 26 January 2021
22 • jid 2020:221 (1 january) • Lartey et al
TFH-cell responses in humans, and, given their vital role in the 
induction of long-term humoral immunity, activation of TFH 
cells is important in the development of new influenza vaccines.
Tonsils are located at the entrance of the upper respiratory 
tract and are compartmentalized organs where follicles and GCs 
develop in response to antigens, such as intranasally admin-
istered LAIV. We have previously shown that LAIV augments 
the local salivary immunoglobulin (Ig)A and tonsillar B-cell re-
sponses in children [5]. In this study, we conducted a clinical 
trial in children and adults to answer the following questions: 
(1) whether LAIV elicits TFH-cell responses in tonsils; (2) are 
there differences in the kinetics and magnitude of tonsillar TFH-
cell responses in children and adults; (3) and whether the LAIV-
induced TFH-cell responses correlate with local and systemic 
antibody responses. Here, we show that LAIV rapidly elicited 
TFH-cell and antibody responses in children and, to a lesser ex-
tent, in adults. Live-attenuated influenza vaccine-induced TFH-
cell responses were inversely associated with pre-existing local 
antibodies, but they positively correlated with antibody induc-
tion after vaccination. Our findings will help to improve under-
standing of the immunogenicity and effectiveness of LAIV in 
age groups with different pre-existing immunity.
MATERIAL AND METHODS
Study Design
Forty children (3–17 years old) and 37 adults (18–51 years old) 
were enrolled in the study after recruitment from the Ear-Nose-
Throat outpatient clinic at Haukeland University Hospital, 
Norway. All subjects were patients scheduled for elective tonsil-
lectomy due to chronic tonsillitis, tonsillar hypertrophy, or both 
but otherwise healthy. The study was approved by the Ethical 
Committee and the Medicines Agency. All participants or their 
guardians provided written informed consent before inclusion 
in the study (NCT01866540, www.clinicaltrials.gov).
Thirty-four children and 31 adults were vaccinated with tri-
valent LAIV (Fluenz; AstraZeneca) during the influenza season 
2013–2014. The children and adults were divided into 3 groups 
and vaccinated on specific days before their scheduled tonsil-
lectomy. Age- and gender-matched unvaccinated subjects (6 
children and 6 adults) were enrolled as controls.
Vaccine and Sampling
Fluenz contained 107 fluorescent focus units (FFUs) of live-
attenuated A/California/7/2009-like (H1N1), A/Texas/50/2012 
(Victoria-like H3N2), and B/Massachusetts/2/2012 strains. The 
vaccine was administered intranasally as 0.1  mL per nostril. 
Children under 9 years old (n = 27) received 2 doses LAIV at 
a 4-week interval as per the manufacturer’s recommendation. 
Children ≥9 years old and adults received a single LAIV dose.
Palatine tonsils were collected during tonsillectomy in 
phosphate-buffered saline. Tonsillar mononuclear cells (TMNCs) 
were isolated from 1 tonsil by Ficoll gradient centrifugation after 
mechanical disruption and cryopreserved at −150oC until use 
[5]. The other tonsil was cut into blocks, fixed in 4% formalde-
hyde, paraffin-embedded, and stored at 4oC until use.
Blood samples were collected before vaccination, on the day 
of tonsillectomy, and up to 1 year after vaccination for vaccinees, 
or only on the day of tonsillectomy for controls. Plasma samples 
were separated, aliquoted, and stored at −80oC until use.
Saliva samples were collected from the lower buccal mu-
cosa before vaccination, on the day of tonsillectomy, and up to 
1 year after vaccination for vaccinees using the OraSure Oral 
Specimen Collection Device (OraSure Technologies). The sam-
ples were stored at −80°C until use.
Hemagglutination Inhibition Assay
Plasma was treated with receptor-destroying enzyme (RDE; 
Seiken) before performing preabsorption with packed turkey 
red blood cells (TRBCs) to remove nonspecific agglutinins. 
The treated plasma samples were analyzed in duplicate (starting 
dilution 1:10) with 8 hemagglutinating units of inactivated 
homologous vaccine strains and 0.7% TRBCs, as previously de-
scribed [5]. The hemagglutination inhibition (HI) titer was de-
termined as the reciprocal of the highest plasma dilution giving 
50% inhibition of hemagglutination. Negative titers (<10) were 
assigned a value of 5 for calculation purpose.
Enzyme-Linked Immunosorbent Assay
Influenza virus-specific Igs were quantified in plasma and sa-
liva samples using the enzyme-linked immunosorbent assay 
(ELISA) developed in-house, as previously described [5]. 
Serially diluted plasma and saliva samples were analyzed in 
Maxi Sorp 96-well plates coated with 2 μg/mL split antigen from 
3 vaccine viruses (kindly provided by GlaxoSmithKline, Wavre, 
Belgium). Immunoglobulin G, IgA, or IgM concentrations were 
interpolated from standard human IgG, IgA, or IgM curves, re-
spectively. For calculation purposes, negatives were assigned as 
0.05 μg/mL in plasma and 1 ng/mL in saliva.
T-Cell Phenotyping, Stimulation, and Flow Cytometry
For T-cell phenotyping, TMNCs were thawed and rested over-
night in complete Roswell Park Memorial Institute (RPMI) 
medium (RPMI 1640 medium containing l-glutamine, peni-
cillin, streptomycin, and amphotericin B; Lonza) supplemented 
with 10% fetal bovine serum (HyClone). For influenza-specific 
T-cell ex vivo stimulation, rested TMNCs were incubated with 
5 μg/mL split antigen from each vaccine virus and anti-CD28 
(CD28.2) and anti-CD49d (9F10) antibodies, brefeldin A, and 
monensin (BD Biosciences).
Rested or stimulated TMNCs were stained with anti-CD3 
(UCHT1), anti-CD4 (SK3), anti-CD19 (HIB19; BioLegend), 
anti-CD56 (NCAM16.2), anti-CD45RA (MEM-56; Thermo 
Fisher Scientific), anti-CXCR5 (J252D4; BioLegend), 
anti-CD57 (NK-1), anti-ICOS (DX29), anti-PD1 (EH12.1), 
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antibodies. To detect Bcl6, the surface-stained cells were fixed 
and permeabilized with FoxP3/Transcription factor staining 
buffer set (eBioscience), followed by staining with anti-Bcl6 
(K112-91) fluorescence-conjugated antibody. All samples were 
incubated with LIVE/DEAD fixable dead cell stain kit (Thermo 
Fisher Scientific) and pooled human sera. All antibodies used 
in flow cytometry were from BD Biosciences, unless otherwise 
specified. Cells were acquired on LSRFortessa cell analyzer (BD 
Biosciences). Data were processed using FlowJo software (ver-
sion 10.4.2 for Mac; TreeStar).
Immunohistochemistry
Paraffin-embedded tonsil sections were single stained with 
anti-Bcl6 (PG-B6p), anti-CD4 (4B12), anti-CD20 (FL-297; 
Santa Cruz), anti-CD57 (TB01), or anti-ICOS (SP98; Novus 
Biologicals), followed by horseradish peroxidase-conjugated 
secondary antibody. All antibodies were from Dako, unless oth-
erwise specified. Stained sections were counterstained with he-
matoxylin and analyzed using light microscopy and Cytation 5 
(BioTek Instruments).
Statistical Analyses
Biological replicates were used in all experiments, unless oth-
erwise stated. Elevations of median fluorescence intensity 
from flow cytometry, HI titers, and Ig concentrations from 
ELISA were Ln transformed before statistical tests. Sidak’s 
multiple comparisons or multiple t tests with desired false-
discovery rate of 1% were performed in a two-way analysis of 
variance. Non-parametric Spearman correlations were tested 
and linear fitting curves were plotted when Spearman P < .10. 
Fisher’s exact analysis was performed with 2 × 2 contingency 




Thirty-four children and 31 adults were divided into 3 groups 
and vaccinated with LAIV on specific days before their sched-
uled tonsillectomy: Group 1 (2–5 days, 7 children and 15 adults), 
Group 2 (6–9 days, 15 children and 8 adults), and Group 3 (10–
22 days, 12 children and 8 adults) (Figure 1 and Supplementary 
Table). Twenty-seven children <9 years old received a second 
dose of LAIV 4 weeks after the first dose. Nine children and 18 
adults had received the 2009 pandemic influenza vaccine, and 
4 children and 5 adults had received prior seasonal influenza 
vaccine(s). Six unvaccinated children and 6 unvaccinated adults 
were enrolled as controls. None of the vaccinees or controls 
had received LAIV before this study. Tonsils and plasma sam-
ples were collected from all subjects on the day of tonsillectomy. 
Sequential pre- and postvaccination plasma and saliva samples 







Day 28 Day 56 Day 180 Day 360 
Groups 1–2–3 





(27 children < 9-year-old) 







(6 children and 6 adults)
Tonsils and plasma
sampling
Figure 1. Illustration of the study design. Forty children (3 to 17 years old) and 37 adults (18 to 51 years old) were enrolled in this study. Thirty-four children and 31 adults 
were vaccinated with trivalent live-attenuated influenza vaccine (LAIV) (Fluenz; AstraZeneca) during the influenza season 2013–2014. The children and adults were random-
ized into 3 groups and vaccinated on specific days before their scheduled tonsillectomy: Group 1 (2–5 days, 7 children and 15 adults), Group 2 (6–9 days, 15 children and 8 
adults), and Group 3 (10–22 days, 12 children and 8 adults). Age- and gender-matched unvaccinated subjects (6 children and 6 adults) were enrolled as controls. Children 
(n = 27) under 9 years old received the second dose LAIV at day 28. Tonsils, plasma, and saliva samples were collected during tonsillectomy. In addition, plasma and saliva 
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Live-Attenuated Influenza Vaccine Elicits Rapid Tonsillar Follicular T 
Helper Cell Responses in Children
Immunohistochemistry (IHC) staining of tonsil sections showed 
that follicles (CD20+ area) and GCs (Bcl6+ area) were present in both 
children and adults tonsils after LAIV. CD4+ T cells were mostly 
found in T-cell zones but occasionally also within GCs. CD57+ 
cells were enriched inside GCs (Figure 2A). In this study, using 
IHC, we observed an increase in ICOS+ area inside follicles after 
LAIV, indicating that LAIV activated follicles in children 7–14 days 
postvaccination (Figure 2B). However, no change in the number 
or size of follicles or GCs was found (data not shown). To further 
study the TFH cells, flow cytometry was used. Tonsillar CD4
+ T cells 
were gated into 3 subsets based on CXCR5 and CD57 expression 



















































































































Figure 2. Activation of follicular T helper cells after live-attenuated influenza vaccine. (A) Representative immunohistochemistry images (original magnification ×4) of 
sections stained with CD4, Bcl6, or CD57 from a child (7 years old, top) and an adult (24 years old, bottom). Stained sections were counterstained with hematoxylin. Scale 
bar indicates 400 μm. (B) A summary of inducible T-cell costimulator (ICOS)+ area inside follicles from controls and vaccinees in Groups 1–3 in children (n = 22) and adults 
(n = 18). Follicles were measured based on CD20 and hematoxylin staining. (C) Representative CD4+ T-cell subsets gating based on CXCR5 and CD57 in a child (4 years old, 
left) and an adult (40 years old, right). Tonsillar mononuclear cells were pregated as CD3+CD19−CD56−CD4+CD45RA− (pregating in Supplemental Figure S1). Numbers adjacent 
to outlined areas indicate frequencies of CD4+ T cells in each subset. (D) A summary of the distribution of the CD4+ T-cell subsets in 12 unvaccinated children and adults. (E) 
The expression of ICOS in median fluorescence intensity (MFI) in CD4+ T-cell subsets: CXCR5+CD57+ (orange), CXCR5+CD57− (blue), and CXCR5−CD57− (red) from unvaccinated 
children and adults. (F) A summary of ICOS expression in MFI from controls and vaccinees in Groups 1–3 in children (n = 25) and adults (n = 23). The mean values are shown as 
bars, and each symbol represents 1 subject (B and D–F). Sidak’s multiple comparisons between CD4+ T-cell subsets were performed in two-way analysis of variance ([ANOVA] 
D and E). Multiple t tests with desired false discovery rate of 1% between vaccinated and unvaccinated subjects were performed in two-way ANOVA (B and F). Data were 
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were CXCR5+CD57+ in children and adults, respectively (Figure 
2C and D). The CXCR5+CD57+ cells expressed the canonical TFH-
cell markers ICOS, PD1, and Bcl6 (Figure 2E and Supplementary 
Figure S2), hence the CXCR5+CD57+ cells are bona fide TFH cells 
[17]. Overall, children vaccinated with LAIV had higher ICOS ex-
pression on TFH cells compared with controls; however, the cell fre-
quency remained unchanged (Figure 2F and data not shown).
To assess influenza-specific TFH-cell responses after LAIV, we ex 
vivo-stimulated TMNCs with vaccine antigens and measured ICOS 
expression as a surrogate of TFH-cell activation [23, 24]. Children had 
significantly increased ICOS expression in TFH cells as early as 3 days 
postvaccination against H1N1 and H3N2 antigens, and at day 7 against 
the B antigen (Figure 3A). The TFH cells in adults had significantly in-
creased ICOS expression 7 days postvaccination, against all 3 antigens 
(Figure 3B). Furthermore, we calculated the total LAIV-induced TFH-
cell responses in each individual (Delta ICOS × CXCR5+CD57+ %). 
Live-attenuated influenza vaccine induced significant TFH-cell responses 
against all 3 viruses in children but only against B virus in adults (Figure 
3C). Overall, our data showed that LAIV elicits rapid antigen-specific 

































































































































CXCR5+CD57+ CXCR5+CD57– CXCR5+CD57+ CXCR5+CD57– CXCR5+CD57+ CXCR5+CD57-
CXCR5+CD57+ CXCR5+CD57– CXCR5+CD57+ CXCR5+CD57– CXCR5+CD57+ CXCR5+CD57–
Figure 3. Live-attenuated influenza vaccine elicits influenza-specific follicular T helper (TFH)-cell responses. (A and B) Influenza-specific inducible T-cell costimulator (ICOS) 
expression increases (Delta ICOS in median fluorescence intensity [MFI]) in CD4+ T-cell subsets from controls and vaccinees in Groups 1–3 in children (n = 25; A) and adults 
(n = 23; B). (C) Vaccine-induced total influenza-specific TFH-cell responses were calculated as the elevation in TFH-cell activity (Delta ICOS × CXCR5
+CD57+ %). Tonsillar mono-
nuclear cells were rested and stimulated with influenza split antigens from A/California/07/2009-like (H1N1) virus (left) or A/Victoria/361/2011-like (H3N2) virus (center) or 
B/Massachusetts/2/2012 virus (right). Results from vaccinees (Groups 1–3) are presented as arbitrary values relative to unvaccinated subjects (Control). The mean values are 
shown as bars, and each symbol represents 1 subject. Multiple t tests with desired false discovery rate of 1% between vaccinated and unvaccinated subjects were performed 
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Live-Attenuated Influenza Vaccine Elicits Early Antibody Responses in 
Children
Having established that LAIV induced rapid TFH-cell responses, 
we assessed early systemic and local antibody responses after 
vaccination. Hemagglutinin (HA)-specific systemic antibodies 
were quantified using the HI assay (Figure 4A). In children, 
increases in HI titers to H1N1, H3N2, and B viruses were ob-
served as early as day 14 (Group 3) after LAIV. In adults, no 
increase in HI titers was observed. Neutralizing antibodies 
measured by microneutralization assay showed similar ki-
netics (data not shown). Influenza-specific antibodies were 
quantified using ELISA. In children, we observed increases in 
systemic IgG against all 3 viruses 14 days after LAIV (Figure 
4B), but we only observed marginal increases in local salivary 
IgA against H3N2 virus (Figure 4C). Adults had higher pre-
existing (D0) antibodies than children, but no increase after 
LAIV. Our data, taken togther, show that LAIV elicits early 
influenza-specific antibody responses in children, but not in 
adults.
Live-Attenuated Influenza Vaccine Elicits Long-Term Antibody Responses 
in Children
We assessed the antibody responses up to 1 year after LAIV. After 
immunization, 6, 10, and 19 of 34 children, and 3, 2, and 5 of 31 
adults seroconverted (≥4-fold increase from prevaccination HI 
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Figure 4. Live-attenuated influenza vaccine elicits influenza-specific antibodies within 14 days in children. Hemagglutinin-specific antibodies (hemagglutination inhibition 
[HI] titer; A) and total influenza-specific antibodies (immunoglobulin [Ig]G; B) were measured using plasma samples before (D0) and after vaccination (DT) from vaccinees in 
Groups 1–3. (C) Virus-specific local antibodies (IgA) were measured using saliva samples before (D0) and after vaccination (DT) from vaccinees in Groups 1–3. Antibodies 
were tested against A/California/07/2009-like (H1N1) virus (left) or A/Victoria/361/2011-like (H3N2) virus (center) or B/Massachusetts/2/2012 virus (right). The geometric 
mean values are shown as bars, and each symbol represents 1 subject. Antibody titers and concentrations were Ln transformed in statistical analyses. Multiple t tests with 
desired false discovery rate of 1% between pre- and postvaccination titers were performed in two-way analysis of variance. The horizontal dotted lines indicate HI titer of 40 
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after LAIV were maintained above protective titer (≥40) for 1 year 
in children against all 3 viruses but only against influenza B in 
adults (Figure 5A).
We quantified the influenza-specific systemic IgG (Figure 
5B), IgA, and IgM (Supplemental Figure S3). In children, 
LAIV elicited significant increases in IgG against all 3 
antigens at 28 days postvaccination, which were maintained 
throughout the year. In contrast, adults showed no increase in 
antibodies after LAIV (Figure 5B). Similar trends, although 
of lower magnitudes, were observed with IgA responses 
(Supplemental Figure S3A). Live-attenuated influenza vac-
cines also induced an IgM response in children against influ-
enza B (Supplemental Figure S3B).
Next, we measured local salivary antibodies up to 56 days after 
vaccination. Live-attenuated influenza vaccine significantly in-
creased the local IgA to influenza B virus in children; however, 
no change was observed in adults (Figure 5C). In summary, our 
data showed that in children, LAIV induced long-term antibody 
responses to all 3 viruses, but local antibodies were only elicited 
against influenza B virus. In adults, only influenza B-specific anti-
body responses were observed after LAIV.
Follicular T Helper Cell Responses After Live-Attenuated Influenza 
Vaccine Correlated With Antibody Responses
Our next aim was to assess whether LAIV-induced TFH-cell re-
sponses correlated with the age of the subject or pre-existing 
H1N1 H3N2 B

















































































D0 D28 D56 D180 D360 D0 D28 D56 D180 D360 D0 D28 D56 D180 D360 D0 D28 D56 D180 D360 D0 D28 D56 D180 D360 D0 D28 D56 D180 D360
*** P = .06 P = .06***
Figure 5. Live-attenuated influenza vaccine elicits long-term influenza-specific systemic and local antibodies in children. Systemic hemagglutinin-specific antibodies 
(hemagglutination inhibition [HI] titer; A) and total influenza-specific antibodies (immunoglobulin [Ig]G; B) were measured using plasma samples prevaccination (D0) and 
28 days (D28), 56 days (D56), 6 months (D180), and 12 months (D360) postvaccination. Local influenza-specific antibodies (IgA; C) were measured using saliva samples before 
vaccination (D0) and 28 days (D28) and 56 days (D56) after vaccination. Antibodies were tested against A/California/07/2009-like (H1N1) virus (left) or A/Victoria/361/2011-
like (H3N2) virus (center) or B/Massachusetts/2/2012 virus (right). The geometric mean titers are shown as bars, and each symbol represents 1 subject. Antibody titers and 
concentrations were Ln transformed in statistical analyses. Sidak’s multiple comparisons between prevaccination (D0) and each time point postvaccination (D28, D56, D180, 
and D360) were performed in two-way ANOVA. The geometric mean HI titers (GMT) at each time point are noted above the graphs, and the horizontal dotted lines indicate 
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local antibody levels. First, we observed an increase in the pre-
existing influenza-specific salivary IgA concentration with an 
increase in age (Figure 6A). Notably, pre-existing salivary IgA 
concentrations inversely correlated with LAIV-induced TFH-cell 
responses (Figure 6B), suggesting that high influenza-specific 
local IgA concentrations present in adults may limit the ton-
sillar TFH-cell responses.
Next, we tested whether tonsillar TFH-cell responses elicited 
after LAIV correlated with systemic antibody induction 
postvaccination. It is interesting to note that LAIV induced 
influenza-specific TFH-cell responses correlated with the sys-
temic IgG fold-induction 28 days after vaccination (D28/D0), 
but not HI titers, against H1N1 and H3N2 antigens (Figure 7A). 
We further dissected antibody responses by stratifying vaccinees 
as naive (HI titer <40) or experienced (HI titer ≥40) before vac-
cination. We were intrigued to find that TFH-cell and antibody 
responses correlated more closely in naive individuals for influ-
enza A (H1N1 and H3N2) viruses. In contrast for influenza B 
virus, TFH-cell and antibody responses significantly correlated 
only in experienced vaccinees (Figure 7B). Similar patterns 
were also observed with antibody responses 56 days after LAIV 
(Supplemental Figure S4). The correlations between TFH-cell 
and systemic IgG responses were confirmed using Fisher’s exact 
test (Supplemental Figure S5). Our data, taken together, dem-
onstrate that LAIV-induced tonsillar TFH-cell responses correl-
ated with systemic antibody responses after vaccination.
DISCUSSION
The mechanisms by which vaccines, particularly live-
attenuated viral vaccines, elicit persistent antibody responses 
remains unclear. Understanding the underlying immunolog-
ical mechanisms that mediate long-term immunity is critical 
in designing improved vaccines. Follicular T helper cells play 
a critical role in GC formation and the development of high 
affinity antibody and B-cell responses [13], thus vaccines that 
successfully promote and maintain TFH cells are most likely 
to induce persistent antibody responses. Our data show, for 
the first time, that LAIV rapidly activated follicles and ton-
sillar TFH cells in children and, to a lesser extent, in adults. 
We also observed rapid and long-term (up to 1 year) antibody 
responses to all 3 vaccine viruses in children, but only to in-
fluenza B virus in adults. The magnitude of tonsillar TFH-cell 
responses was inversely correlated with pre-existing local IgA 
antibodies. More important, significant correlations were ob-


































































































Figure 6. Pre-existing local antibodies correlate with age and follicular T helper (TFH)-cell responses after live-attenuated influenza vaccine (LAIV). (A) Pre-existing influenza-
specific local antibodies (immunoglobulin [Ig]A) in saliva samples from children and adults correlated strongly with their ages. (B) The LAIV-induced TFH-cell responses (Delta 
inducible T-cell costimulator [ICOS] × CXCR5+CD57+ %) inversely correlate with pre-existing influenza-specific local antibodies (IgA). The TFH-cells activity and antibodies were 
tested against split antigens from A/California/07/2009-like (H1N1) virus (left) or A/Victoria/361/2011-like (H3N2) virus (center) or B/Massachusetts/2/2012 virus (right). 
Pre-existing IgA concentrations in saliva samples were Ln transformed in statistical analyses. Linear fitting curve was plotted as dotted line when nonparametric Spearman 
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Recent studies have shed light on the tonsillar TFH-cell re-
sponses against influenza in humans [25, 26]. In children re-
ceiving IIV, Amodio et  al [25] found a significant increase 
in the frequencies of TFH cells, which were associated with 
influenza-specific, antibody-secreting cells. Aljurayyan et  al 
[26] in vitro stimulated TMNCs from unvaccinated individuals 
with attenuated influenza viruses and reported TFH-cell activa-
tion, proliferation, and differentiation, which correlated with 
antibody production. In our study, using IHC, we showed that 
a substantial number of CD4+ and CD57+ cells are present in-
side follicles, in agreement with previous observations [18, 19]. 
Immunohistochemistry showed that follicles inside tonsils were 
activated after LAIV, indicated by the elevated ICOS expression. 
However, no change in follicle number or size was found after 
vaccination, suggesting the absence of a strong GC reaction. 
Flow cytometric analyses also showed higher ICOS expression 
in the TFH-cell (CXCR5
+CD57+CD4+ T cell) population, sug-
gesting increased TFH-cell activation, although the TFH-cell fre-
quencies remained unchanged after LAIV. The lack of increase 
in TFH-cell frequencies after LAIV vaccination may be attrib-
uted to the replicating nature of the LAIV with a relatively low 
antigen dosage (107.0 ± 0.5 FFU) compared with IIV (commonly 
15 μg of HA per strain). However, when LAIV-specific TFH-cell 
responses were ex vivo stimulated, we observed potent TFH-cell 
responses against all 3 LAIV viruses in children and against the 
B virus in adults (Figure 3). Future studies on tonsillar TFH-cell 
and circulating TFH-like-cell responses after LAIV will help gain 
insights into the relationship between these lymph node and 
systemic TFH cells and to establish whether circulating TFH-like 
cells are a possible biomarker for the immunogenicity of LAIV.
To dissect humoral responses after LAIV, we quantified sys-
temic influenza-specific antibodies as HA-specific functional 
and binding antibodies in plasma samples. In addition, local IgA 
were measured in saliva samples (Figures 4 and 5). The HI titer 
of 40 has been widely used as a surrogate correlate of protection 
[27], although an HI titer of 110 was suggested for protection 
against H3N2 in children [28]. Recent studies have shed light on 








































































































Figure 7. Influenza-specific follicular T helper (TFH)-cell responses after live-attenuated influenza vaccine (LAIV) correlate with antibody responses. (A) The correlations 
between LAIV-induced TFH-cell responses (Delta inducible T-cell costimulator [ICOS] × CXCR5
+CD57+ %) and systemic antibody fold induction (plasma immunoglobulin [Ig]G 
D28/D0) from all vaccinated children and adults. (B) Influenza A viruses specific TFH-cell and antibody responses correlate in naive individuals (D0 hemagglutination inhibition 
[HI] <40), whereas influenza B virus-specific TFH-cell and antibody responses correlate in pre-exposed individuals (D0 HI ≥40). The TFH-cell responses and antibody fold induc-
tion were tested against split antigens from A/California/07/2009-like (H1N1) virus (left) or A/Victoria/361/2011-like (H3N2) virus (center) or B/Massachusetts/2/2012 virus 
(right). Systemic antibody fold inductions (plasma IgG D28/D0) were Ln transformed in statistical analyses. Linear fitting curve was plotted as dotted line when nonparametric 
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neuraminidase and internal protein-specific antibodies may 
contribute to elimination of infection through limiting progeny 
virion release and mechanisms such as antibody-dependent, 
cell-mediated cytotoxicity [29, 30]. Meanwhile, mucosal IgA 
provides protection against the initial establishment of infec-
tion [4]. We found significant increases in influenza-specific 
antibodies 14 days after LAIV, which were maintained for up 
to 1 year in children to all 3 viruses. However, in adults, LAIV 
only elicited antibodies to the B virus. These differences in the 
immunogenicity among vaccine viruses observed are consistent 
with previous findings [31], and they could be due to differences 
in virus replication efficiency in the upper respiratory tract. In 
addition, although we only observed low local IgA responses 
after LAIV using saliva samples (Figures 4 and 5), future studies 
could measure IgA in nasal washes to gain more direct evidence 
of mucosal antibody responses after LAIV.
During the 2009 pandemic, Norway vaccinated its popula-
tion with AS03-adjuvanted pandemic vaccine, which induced 
durable antibody responses [32]. Among the vaccinees in our 
cohort, 27% of children and 52% of adults had received this 
pandemic vaccine. We observed higher pre-existing H1N1 HI 
titers in these individuals (P =  .03 in children and P =  .002 in 
adults) (Supplemental Figure S6), consistent with our previous 
findings [33]. The higher frequency of adults receiving pandemic 
vaccine may help explain the higher H1N1-specific pre-existing 
antibodies and subsequently the lower antibody responses after 
LAIV in adults compared with children. In future studies, a com-
parison of TFH-cell responses elicited by IIV and LAIV may pro-
vide better insight into understanding differences in the immune 
responses elicited by parenteral and intranasal influenza vaccines.
In Europe, LAIV is only licensed and recommended for 
children 2–17 years old, because LAIV elicits more potent and 
longer-lasting immune responses in children than in adults [2, 
33]. Our analyses revealed 3 correlations: (1) the pre-existing 
local IgA correlates with age; (2) LAIV-induced TFH-cell re-
sponses inversely correlate with the pre-existing local IgA; and 
(3) systemic antibody responses after vaccination correlate with 
TFH-cell responses. Our data, taken together, may explain why 
LAIV works better as priming vaccine in children [34]. The 
low pre-existing local antibody levels at the site of LAIV ad-
ministration in children may aid virus replication, thus leading 
to the generation of rapid TFH-cell responses and subsequent 
long-term humoral responses after vaccination. In contrast, 
higher pre-existing local antibodies in older individuals, likely 
due to previous exposure or vaccination, may partially inhibit 
the initial LAIV virus replication. As a result, LAIV elicits lower 
TFH-cell activation in adults, which provides insufficient B-cell 
help, and consequently lower humoral responses after vaccina-
tion. We found that LAIV-induced TFH-cell responses inversely 
correlated more strongly with pre-existing local IgA than age, 
implying that LAIV functions optimally as a priming vaccine on 
no or low background immunity. It is interesting to note that 
TFH-cell and antibody responses correlate significantly in naive 
vaccinees with H1N1 and H3N2 viruses but with B virus in pre-
exposed vaccinees. This could be explained by influenza B virus 
being better adapted to humans than influenza A viruses, thus 
lower TFH-cell activation is needed for antibody induction (as 
confirmed in the Fisher’s exact test) (Supplementary Figure S5). 
Further studies with a larger cohort are needed to validate our 
findings.
CONCLUSIONS
In this study, we assessed the kinetics and magnitude of LAIV-
induced TFH-cell, systemic, and local antibody responses in 
children and adults. In this study, for the first time, we have 
shown that LAIV elicits rapid tonsillar TFH-cell responses to all 3 
influenza vaccine viruses, which correlated with the long-term 
systemic antibody increases after vaccine. Our data will con-
tribute to the understanding of mechanisms that govern LAIV-
induced immune responses in pediatric and adult populations.
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